Partnering with
Eleva Biologics
Eleva Biologics is an indispensable strategic partner for the discovery and co-development of highly complex biologics.
Our moss-based platform allows the development of biologics with highly differentiated competitive product profiles that are difficult or impossible to achieve with other available production systems, including recombinant antibody modalities, multi-domain fusions, and structurally complex blood proteins.
The platform preserves correct folding and assembly of highly complex proteins including multi-domain fusions and complex blood proteins. Additionally, the platform offers precise control over glycosylation and ensures homogeneous protein production. Our GMP-validated platform has produced two moss-derived candidates that have entered EMA-authorized clinical development.
We are open to engagement at multiple levels of commitment, from a single feasibility on one asset to a programmatic platform relationship. Tell us what you are working on; we will tell you whether moss can move it.
Contact person
Dr. Christian Abraham, MBA
Director Strategic Alliances
Our Strategic Alliance with 3PBIOVIAN
Benefits of the Partnership:
Increased GMP Production Capacity: Our collaboration with 3PBIOVIAN has tripled our GMP production capacity, enabling us to produce clinical materials faster and more efficiently. This expansion is crucial for advancing our pipeline programs and supporting the needs of our partners.
Innovative Solutions: The combination of Eleva Biologics’ moss-based platform with 3PBIOVIAN’s manufacturing expertise opens up new possibilities for the development of biologics. This synergy allows us to offer innovative solutions that were previously unattainable.
Accelerated Time to Market: By leveraging the strengths of both companies, we can accelerate the clinical development process and bring new therapies to market more quickly. This partnership enhances our ability to meet the evolving needs of biopharmaceutical developers.
Next Page
